OverviewSuggest Edit

OptiBiotix Health PLC, formerly Ducat Ventures PLC, is a United Kingdom-based life sciences company developing compounds to tackle obesity, high cholesterol and diabetes. The Company develops a range of compounds which modify the human microbiome (the collective genome of the microbes in the body), to prevent and manage human disease. The Company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The product development pipeline is fuelled by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds. These platforms are applicable across a range of other human diseases.
TypePublic
HQHeslington, GB
Websiteoptibiotix.com

Latest Updates

Employees (est.) (Feb 2019)8(+60%)
Revenue (FY, 2018)£514.3 K(+170%)
Share Price (Oct 2017)£0.7 (-4%)

Optibiotix Health Office Locations

Optibiotix Health has an office in Heslington
Heslington, GB (HQ)
Innovation Way
Show all (1)

Optibiotix Health Financials and Metrics

Optibiotix Health Revenue

Embed Graph
View revenue for all periods
Optibiotix Health's revenue was reported to be £514.29 k in FY, 2018 which is a 169.2% increase from the previous period.
GBP

Revenue (FY, 2018)

514.3k

Revenue growth (FY, 2017 - FY, 2018), %

169.2%

Gross profit (FY, 2018)

351.5k

Gross profit margin (FY, 2018), %

68.3%

Net income (FY, 2018)

(1.9m)

EBITDA (FY, 2018)

(1.4m)

EBIT (FY, 2018)

(1.5m)

Market capitalization (31-Oct-2017)

55.4m

Closing stock price (31-Oct-2017)

0.7

Cash (30-Nov-2018)

1.3m
Optibiotix Health's current market capitalization is £55.4 m.
GBPFY, 2016FY, 2017FY, 2018

Revenue

288.1k191.1k514.3k

Revenue growth, %

922%(34%)169%

Cost of goods sold

38.2k73.7k162.8k

Gross profit

249.9k117.4k351.5k
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

858.0k870.9k819.7k779.3k13.5k27.6k150.02.9m2.0m3.1m1.2m1.3m

Accounts Receivable

16.6k111.5k4.7k62.6k79.2k20.2k228.8k

Inventories

48.2k340.9k26.6k8.9k30.4k

Current Assets

870.4k875.6k822.2k782.9k113.3k480.1k301.4k2.9m2.2m3.5m1.5m2.0m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(55.0k)(31.8k)(15.6k)(36.3k)(256.4k)(1.7m)(2.2m)(810.7k)(1.3m)(1.3m)1.9m(1.9m)

Cash From Operating Activities

38.6k27.6k(63.1k)(42.3k)(195.2k)(1.1m)(502.4k)(680.5k)(983.5k)(1.2m)(1.8m)(1.2m)

Purchases of PP&E

(1.1k)(2.0k)

Cash From Investing Activities

250.7k(2.0k)
GBPY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Optibiotix Health Operating Metrics

H1, 2016

Patents Issued

44

Patents and Patent Applications

14
Show all operating metrics

Optibiotix Health Online and Social Media Presence

Embed Graph

Optibiotix Health Blogs

Duo of new SlimBiome® products to launch in India

OptiBiotix Health PLC (‘OptiBiotix’), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, has announced the commercial launch of two innovative new health products containing SlimBiome® to the Indian market. In partnership with fully integrated pharm…

How to identify the signs of poor gut health

The world of science and medicine is only just beginning to uncover the full extent of the gut microbiome’s effect on overall health and wellness, which makes it an exciting time in the sphere of gut-mediated wellness. Father of modern medicine Hippocrates claimed over 2000 years ago that ‘all disea…

OptiBiotix announces trio of new commercial agreements

OptiBiotix Health Plc (‘OptiBiotix’), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, has announced the details of three new commercial agreements, extending the geographic reach of its SlimBiome® and GoFigure® brands in 2020. Exclusive supplier …

CholBiome®x3 to bring non-pharmaceutical cholesterol management to the Philippines

OptiBiotix Health PLC (‘OptiBiotix’), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, has announced the details of a new distribution agreement that will see CholBiome®x3, supplied by fully owned subsidiary ProBiotix Health Ltd (‘ProBiotix’), mad…

OptiBiotix prepares for CholBiomeX3 launch with Akums Pharmaceuticals

OptiBiotix Health PLC (‘OptiBiotix’), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, has continued its impressive market expansion by visiting manufacturing and distribution partner Akums Drugs and Pharmaceuticals Pvt. Ltd. (‘Akums Pharmaceutica…

New GoFigure Website Launches in Poland

OptiBiotix Health Plc., a leading life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, has co-launched www.GoFigure.pl, a brand new e-commerce platform for its science-backed weight management product range GoFigure® in the Polish market in collabor…
Show more

Optibiotix Health Frequently Asked Questions

  • How many employees does Optibiotix Health have?

    Optibiotix Health has 8 employees.

  • What is Optibiotix Health revenue?

    Latest Optibiotix Health annual revenue is £514.3 k.

  • What is Optibiotix Health revenue per employee?

    Latest Optibiotix Health revenue per employee is £64.3 k.

  • Who are Optibiotix Health competitors?

    Competitors of Optibiotix Health include Foundation Medicine, TxCell and Instem.

  • Where is Optibiotix Health headquarters?

    Optibiotix Health headquarters is located at Innovation Way, Heslington.

  • Where are Optibiotix Health offices?

    Optibiotix Health has an office in Heslington.

  • How many offices does Optibiotix Health have?

    Optibiotix Health has 1 office.